MMRF PRESS RELEASES
The Multiple Myeloma Research Foundation Designated to Receive Portion of Sales from New Geraldine Ferraro Commemorative Rose from Jackson & Perkins
NORWALK, Conn. — January 29, 2007
NORWALK, Conn., January 29 -- The Multiple Myeloma Research Foundation (MMRF), the world's leading private funder of multiple myeloma research, today announced that Jackson & Perkins will designate ten percent of the net sales proceeds to the organization from a new commemorative hybrid tea rose named in honor of Geraldine Ferraro to support its innovative mission.
Ferraro, who was diagnosed with multiple myeloma in 1998, said, "On behalf of the millions of victims, survivors, and families affected by multiple myeloma, I am both honored and humbled to have this beautiful Jackson & Perkins rose named after me. This rose, which will benefit the life-saving work of the MMRF, is both a celebration of the progress we have made so far in combating this disease, and is also a stark reminder of how far we still have to go in terms of research and treatment."
The rose will be introduced by Jackson & Perkins at a special ceremony on Monday, January 29 (9:45 AM) at Fordham Law School to pay tribute to Geraldine Ferraro – the former Congresswoman of the United States, United Nations ambassador, and the first female candidate for Vice President – both as a public figure and as a survivor of multiple myeloma. The light pink rose with pointed buds that spiral open into soft pink, densely petaled flowers and a wonderful anise aroma was personally selected by Ms. Ferraro.
"Geraldine Ferraro has inspired countless cancer patients to maintain their courage and dignity in battling their disease through exceptional candor about her own personal experience," said Kathy Giusti, Founder and Chief Executive Officer of MMRF, and myeloma patient. "We gratefully accept this generous contribution which will contribute toward the organization's investment in cutting-edge research to bring much-needed new therapies to myeloma patients."
Jackson & Perkins' nationally renowned rose hybridizer, Dr. Keith Zary, worked closely with Ms. Ferraro to designate this beautiful rose. The rose will be available exclusively in the Jackson & Perkins catalog in January 2007 or at www.jacksonandperkins.com. The rose is sold for $19.95 for a single rose or $54.95 for three, plus delivery and handling charge. The Geraldine Ferraro Rose joins a significant list of cause roses that honor prominent leaders and organizations with proceeds being donated to designated charities.
About Multiple Myeloma
Multiple myeloma, an incurable cancer of the plasma cell, represents one percent of all cancer diagnosis and two percent of all cancer deaths. Despite recent advances in treating multiple myeloma, the five-year survival rate for multiple myeloma is only 32 percent, one of the lowest of all cancer. Approximately 50,000 people in the United States are living with multiple myeloma and an estimated 20,000 new cases are diagnosed each year. Although the peak age of onset of multiple myeloma is 65 to 70 years of age, recent statistics suggest that incidence is increasing and at an earlier age.
About the Multiple Myeloma Research Foundation (MMRF)
The Multiple Myeloma Research Foundation (MMRF) was established in 1998 as a 501(c)3 non-profit organization by twin sisters Karen Andrews and Kathy Giusti, a newly diagnosed multiple myeloma patient, with the unique mission of accelerating the search for a cure for multiple myeloma. As the world's number one funder of myeloma research, the MMRF has raised more than $70 million to fund more than 215 research grants at more than 75 research institutions around the globe. Currently, the MMRF is funding more than 30 new compounds and approaches – in pre-clinical testing and Phase I, II and III clinical trials – that show promise in treating patients at all stages of the disease. For more information about the MMRF, please visit www.themmrf.org.
Vicki Vlastaris (MMRF)